• Jianwei Su, Yixuan Wang, Wanping Zhong, Mengzhi Wang, and Yanhong Wang.
• Department of Clinical Pharmacy, Dongguan Tungwah Hospital, Dongguan, Guangdong, China.
• Arch Med Sci. 2024 Jan 1; 20 (2): 675678675-678.

IntroductionThere is insufficient evidence in statin on the treatment of Staphylococcus aureus (SA) infection, we observe and analyze the clinical outcomes and antibiotic resistance of SA bloodstream infections in patients who received statins.MethodsA retrospective study was carried out in SA bloodstream infection of hospitalized patients from January 2018 to August 2023. The 30-day attributable mortality, 30-day all-cause mortality and clinical data of patients who received statins and non-statins were compared.ResultsA total of 74 patients with SA bloodstream infection were included, 32 (43.2%) patients received treatment with statins and 42 (56.8%) with non-statins. The incidence of methicillin-resistant SA (MRSA) was significantly lower in the statins group (15.6% vs. 38.1%, p = 0.034), however, no significant differences were observed in the mortality rate (p = 0.410).ConclusionsThis study revealed the superiority of statins in reducing incidence of MRSA among SA bloodstream infection patients, but statins do not improve the 30-day mortality rate.Copyright: © 2024 Termedia & Banach.

5 keywords...

hide…